Curriculum vitae of Mario Romano, M.D.

ORCID ID: https://orcid.org/0000-0001-8512-1458

Personal Information

Name: Mario Romano

Place of birth: Messina, Italy

Date of birth: May 19, 1954

Office Address: Laboratory of Molecular Medicine
Center on Advanced Studies and Technology (CAST)
"G. d'Annunzio" University of Chieti-Pescara, Italy
Via Luigi Polacchi 11/13
66100 Chieti
Phone: 0871-541475

E-mail: mromano@unich.it

Education

1984	Fellowship in Hematology with honors	University of Catania
1982	Short Course in Hematology	R.P.M.D. London
1981	Fellowship in Lung Diseases with honors	University of Messina
1978	Degree in Medicine with honors	University of Messina

Employment and Academic Ranks

2018-to date	Full Professor of Laboratory Medicine	"G. d'Annunzio" University, Chieti-Pescara, Italy
2003-2018	Associate Professor of Laboratory Medicine	"G. d'Annunzio" University, Chieti-Pescara, Italy

2002-to date	Director Molecular Medicine	"G. d'Annunzio" University, Chieti-Pescara, Italy
2002-2003	Assistant Professor	"G. d'Annunzio" University, Chieti-Pescara, Italy
1990-'94	Research Associate in Medicine	Harvard Medical School, Boston MA, USA
1988-1990	Visiting Scientist	Mario Negri Sud, S. Maria Imbaro, Italy
1986-1988	Research Associate	Harvard Medical School, Boston MA, USA
1984	Visiting Scientist	I.N.S.E.R.M.-U.91, Créteil, France
1983-1986	Visiting Scientist	Mario Negri Institute, Milan
1982-2001	Assistant Professor	University of Messina, Italy
1978-1982	Internship in Medical Pathology	University of Messina, Italy

Institutional Responsibilities

2019-to date	Member of the Research Commission of the Department of Medical, Oral e Biotechnological Sciences, "G. d'Annunzio" University of Chieti-Pescara.
2014-2019	Referent for the "G. d'Annunzio" University of Chieti-Pescara of the WHRI-Academy program (http://whri-academy.eu).
2013-to date	Member of the Inter-Institutional Ethical Committee for Animal Studies, "G. d'Annunzio" University of Chieti-Pescara.

Honors and Awards

2017. Prize from the Italian Cystic Fibrosis Foundation for innovative research in the Cystic Fibrosis field.

2009. Invitation as opponent in the PhD thesis dissertation "Studies on coactosin-like protein interaction with 5-Lipoxygenase" at the Karolinska Institutet, Stockholm, Sweden.

Advisory Boards

2012- to date Editor, Frontiers in Pharmacology – Respiratory Pharmacology

Reviewer for: Biochim. Biophys. Acta, Thromb. Haemost., Eur. J. Cancer, Circulation, Exp. Cell Res., FASEB J., J. Cyst. Fibros., Atherosclerosis, Clin. Chem. Lab. Med., Biochem. J., Eur. Resp. J., Atheroscl. Thromb. Vasc. Biol., Am. J. Hematol., J. Biol. Chem., J. Mol. Biol., J. Nutrigen. Nutrigenom., J. Ocul. Pharmacol. Ther, TSWJ, J. Pharmacol. Exp. Ther., Lett. Drug. Des. Discov., Clin. Chem. Lab. Med., J. Cell Mol. Med., Int. J. Biochem. Cell Biol., Cell Proliferat., Eur. J.

Pharmacol., Med. Chem. Commun., Tumor Biol., Lett. Drug Des. Discov., Environ. Tox. Pharmacol., Platelets. Vasc. Pharmacol., Biochem. J., Eur. Heart J., Curr. Rheumathol. Rev., PNAS, Nutrition Res., Am. J. Biotechnol., Oncotarget, BBADIS, BBAGRM, Curr. Rheumathol. Rev., PlosOne, Eur. J. Pharmacol., POLM, J. Biom. Sci., Sci. Rep., Clin. Immunol. End. Met. Drugs, Stem Cell Intern., Mediat. Inflamm. Cell. Physiol. Biochem., Frontiers Pharmacol., Frontiers Immunol., Trends Immunol., J. Immunol., Stem Cell Transl. Med.

Reviewer for the following international granting agencies:
HRB, FCT, BSF, ANR, Barts Charity, Cystic Fibrosis Trust

Scopus Parameters

H-index	34
Citations	3343

Scientific Achievements

Mario Romano first studies concerned important non-haemostatic aspects of platelet function and were communicated by prof. Romano at U.C.L.A. Conference of Park City of 1984 and then published in the form of a letter in *The Lancet 2 (8502): 345, 1986* and as an editorial in *Haematologica 71: 359-361, 1986*. Studies on platelets continued during the first stay of prof. Romano in Boston at Harvard University. During this period prof. Romano identified an intracellular signaling pathway activated in platelets by the bacterial lipopolysaccharide. The results of these studies were communicated by prof. Romano with an oral report to the American Society for Clinical Investigation held in Washington D.C. in 1988 and then published (*J. Biol. Chem. 265: 1765-1770, 1990).* An extension of these studies carried out in the laboratories of the Mario Negri Sud Consortium, where prof. Romano spent some periods between 1988 and 1990, lead to the identification of additional signal pathways triggered by lipopolysaccharide in platelets (*Biochem. J. 278: 75-80*).

His knowledge of platelet pathophysiology earned him the invitation from prof. Charles Serhan, the undisputed world leader in the field of lipid mediators in inflammation resolution to join his laboratory at Harvard University. During the period spent in prof. Serhan Laboratory (1990-1994), prof. Romano discovered some of the platelet-dependent molecular mechanisms of lipoxin biosynthesis and signaling, while contributing to the initial characterization of the lipoxin A_4 receptor (*Biochim. Biophys. Acta 1133: 224-234, 1992; Biochemistry 31: 8269-8277, 1992; Biochem. J. 296: 127-133, 1993; J. Clin. Invest. 92: 1572-1579, 1993; Blood 81: 3395-3403, 1993; J. Immunol. 157: 2149 -2154, 1996*).

Returning to Italy, prof. Romano was offered the opportunity to organize a research laboratory at the G. d'Annunzio University of Chieti-Pescara. Over the years, this laboratory has become a national and international reference for its contribution to the knowledge of the mechanisms, in particular those related to the metabolism of arachidonic acid, of the inflammatory response in different pathophysiological contexts. The laboratory of prof. Romano has developed a new methodology for measuring lipoxin A_4 in biological fluids (*Lab. Invest. 82: 1253-1254, 2002*). This method has been successfully used in various preclinical and clinical studies (*Am. J. Physiol. 277 (46): C870-C877, 1999; J. Appl. Physiol. 94: 2237-2240, 2003; Exp. Gerontol. 40: 612-614, 2005; Ann. Allergy Asthma Immunol. 109: 226-227, 2012; Br. J. Clin. Pharmacol. 69: 303-306, 2010; Proc. Natl. Acad. Sci. USA 100: 10937-10941, 2003*). In the latter study, the contribution of prof. Romano laboratory was instrumental in measuring the urinary excretion levels of 15-epi-lipoxin A_4 for the first time in vivo, thus allowing useful information to be obtained regarding the involvement of this lipid mediator in specific pathophysiological conditions. The technical skills of prof. Romano laboratory have been of significant importance for determining the biosynthesis of 15-epi-lipoxin A_4 in animal models of gastric resistance to aspirin (*Gastroenterology 123: 1598-1606, 2002; FASEB J. 17: 1171-1173, 2003*).

The laboratory of prof. Romano contributed significantly to the identification of the lipoxin A_4 lipoxin receptor (initially defined FPRL-1, recently renamed ALX/FPR2) as a signal transducer triggered by the urokinase-type plasminogen activator receptor (uPAR) (*Proc. Natl. Acad. Sci. USA 99: 1359-1364, 2002*). Moreover, it mapped and functionally characterized the promoter region of the ALX/FPR2 gene, which seems to be of primary importance in controlling the inflammatory response and its resolution, and to discover in a patient with a history of myocardial infarction and metabolic syndrome, as well as in his two daughters, both suffering from juvenile hypertension and metabolic syndrome, a gene variant of this promoter which strongly reduces its transcriptional activity (*FASEB J. 26: 1323-1333, 2012).* These studies, which led to the issue of a European and a North American Patent which see prof. Romano holder of 70% of the intellectual property of the invention, open interesting scenarios for understanding the role of inflammation resolution in vascular and metabolic diseases, as well as in the field of drug discovery for personalized medicine. A project related to this topic that sees prof. Romano as head of one of the participating units, was funded by MIUR in 2011. Additional funding for the studies on ALX/FPR2 receptor was provided by the Swiss pharmaceutical industry Actelion and the Fondazione Bancaria Carichieti during 2012. More recently, the laboratory of Prof. Romano characterized a series of epigenetic regulatory mechanisms of the expression of the ALX/FPR2 gene, identifying elements of particular relevance in microRNA-181b and in post translational modifications of histones (*J. Biol. Chem. 290: 3592-3600, 2015; BBAGRM 859: 1252-1258, 2016*).

Further studies on the relationship between inflammation, platelet activation, endothelial dysfunction, dysmetabolisms and vascular diseases have been published by prof. Romano (*Circulation 92: 3304-3311, 1995; Circulation 97: 953-957, 1998; Diabetes Care 24: 1674-1678, 2001; J. Clin. Endocrinol. Metab. 88: 5321-5326, 2003; J. Thromb. Haemost 11: 2330-2334, 2003; J. Am. Coll. Cardiol. 49: 2182-2190, 2007; Thromb. Haemost. 101: 687-690, 2009; J. Clin. Endocrinol. Metab. 97: E1726-1730, 2012; J. Clin. Endocrinol. Metab. 97: E1726-1730, 2012*).

More recently the laboratory of prof. Romano has contributed significantly to the development of methods for the evaluation of circulating endothelial events (mature cells, precursors, extracellular vesicles) (*Blood 112: 1085-1090, 2008; J. Immunol. Methods 380: 16-22, 2012*). These studies represent an important basis for the correct execution of clinical studies aimed at assessing the involvement of the endothelium during pathological events. These methods have been used as part of a series of projects concerning the role of the endothelium in the inflammation of cystic fibrosis, funded from 2012 to 2016 by the Italian Foundation for the study of Cystic Fibrosis.

The laboratory of prof. Romano has also provided important contributions for understanding the relationship between the inflammatory response, in particular the lipoxygenase metabolism of arachidonic acid and tumors. It was in fact the first to demonstrate that 5-lipoxygenase regulates the release of VEGF, as well as the p53-dependent chemosensitivity of neoplastic cells (*FASEB J. 15: 2326-2336, 2001; FASEB J. 18: 1740-1742, 2004*). Prof. Romano's vision of these phenomena was reported in two highly cited reviews (*FASEB J. 17: 1986-1995, 2003; Curr. Pharm. Design 11: 3431-3447, 2005*). Cancer studies also covered other aspects related to the role of oncogenic viruses (*Oncogene 21: 2896-2900, 2002*) and telomerase activity (*Am. J. Pathol. 159: 721-731, 2001*). Studies in the field of cancer have been supported by public (FIRB 2001-2004; PRIN 2002-204; Ministry of Health (2003-2005); and private grants (Alfa Wassermann 2003-2005).

In the last 15 years the laboratory of prof. Romano has actively studied the pathogenetic mechanisms of inflammation in cystic fibrosis. These studies, funded by the Italian Foundation for the Study of Cystic Fibrosis (2005-2016), led to the first identification of the expression and activity of the CFTR ion channel in human platelets and to the discovery that this channel controls the production of endogenous lipoxin anti-inflammatory mediators, which is deficient in cystic fibrosis (*FASEB J. 24: 3970-3980, 2010*). A proteome analysis also revealed abnormalities in platelets of from patient with cystic fibrosis, compatible with a pro-inflammatory state (*Mol. Biosyst. 7: 630-639, 2010).*

Subsequent studies, starting from an early clinical observation (*Thromb. Haemost. 86: 1363-1367, 2001*) led the laboratory of prof. Romano to develop a new method to isolate, purify and immortalize endothelial cells from cystic fibrosis patients for the first time (*Lab. Invest. 97: 1375-1384, 2017*) and to characterize a series of CFTR functions in these cells, identifying new pharmacological strategies for the control of endothelial dysfunction in cystic fibrosis (*Biochim Biophys Acta. 1863:3243-3253, 2017).*

Very recently the laboratory of prof. Romano has shown that the control circuit of the expression of the anti-inflammatory receptor ALX/FPR2 regulated by the microRNA-181b is altered in the macrophages of volunteers with cystic fibrosis, as well as in the respiratory epithelial cells that express the mutated genotype F508del/F508del (*Sci. Rep. Oct 18; 7 (1): 13519. Doi: 10.1038 / s41598-017-14055-y, 2017*). These results with confirm that cystic fibrosis has defects in the mechanisms of resolution of the inflammatory response and that the correction of these mechanisms may represent a new strategy to combat chronic inflammation of this pathology.

Along these lines, studies coordinated by Dr. Antonio Recchiuti, leader for Experimental and Translational Pharmacology of Resolution Unit within Prof. Romano laboratory, have highlighted the anti-inflammatory and anti-microbial activities at lung level of resolvin D1, an endogenous anti-inflammatory lipid which, like lipoxin A_4, activates the ALX/FPR2 receptor, in health (*FASEB J. 28: 3090-3102, 2014; Mucosal Immunol. 11:35-49, 2018*) as well cystic fibrosis state (*Frontiers Pharmacol. 2020, in press*).
Overall, these studies have helped to critically review the epithelial-centric view of the pathogenesis of inflammation in cystic fibrosis, providing evidence of new pathophysiological functions of the CFTR channel in the different cell types and therapeutic alternatives to combat lung inflammation in cystic fibrosis.

In view of the development of new therapeutic approaches towards inflammatory diseases, very recently the laboratory of prof. Romano, in collaboration with colleagues from the Department of Medical, Oral and Biotechnological Sciences and from the School of Pharmacy of the G. d'Annunzio University of Chieti-Pescara, has developed, using electrospinning technology, a lipoxin A_4-releasing biomembrane (*Int. J. Pharm. 515: 254-261, 2016).* These studies led to the filing of an Italian and European patent application, of which prof. Romano holds 20% of intellectual property.

The initial studies on transcellular metabolism that led to the discovery of lipoxins in the 1980s were recently taken up by the laboratory of prof. Romano, analyzing a new paradigm: the transfer of microRNAs through the release of micro-vesicles. The laboratory of prof. Romano has shown for the first time that the endogenous anti-inflammatory lipid lipoxin A_4 can condition the release of micro-vesicles by endothelial cells, modifying the content of specific microRNAs, in order to promote the resolution of the inflammatory response (*FASEB J. 31: 1856-1866, 2017*). These observations open interesting scenarios for understanding the pathophysiology of the inflammatory response and its resolution and in this direction go the studies conducted by the laboratory of prof. Romano on stem cells. In particular, it has been shown for the first time that stem cells isolated from the periodontal ligament produce and release lipid mediators that promote the resolution of the inflammatory response, indicating that the release of these mediators could be the basis of stem cell immunomodulatory activities (*Stem Cell Transl. Med. 5: 20.32, 2016*). On the basis of evidence from this study and others not yet published on stem cells of patients with cystic fibrosis, an Italian patent application was filed, of which prof. Romano holds 50% intellectual property.

Professor Romano is the author of numerous reviews by invitation (*J. Lipid Mediators Cell Signaling 12: 293-306, 1995; Prostag. Leukotr. Ess 73: 239-243, 2005; Inflammation & Allergy - Drug Targets 5: 81-90, 2006; The Scientific World Journal 7: 1393-412, 2007; Curr. Ped. Rev 5: 8-27, 2009; The Scientific World Journal 10: 1048-1064, 2010, Eur. J. Pharmacol. 760: 49-63, 2015; Stem Cells Transl Med. 8:992-998, 2019*) and a chapter in the book: Lipoxin, Resolvins and the Resolution of Inflammation. In Lipoxygenases in Inflammation, Dieter Steinhilber, Editor, p. 211-240. Progress in Inflammation Research, Springer, 2016.

Funded Projects

- 2019-2021 American Cystic Fibrosis Foundation - P.I.
- 2018 Italian Ministry of the University and Scientific Research FFABRA 2018
- 2018-2020 Italian Cystic Fibrosis Foundation - P.I.
- 2017-2020 Italian Ministry of Health L. 548/93 Program - P.I.
- 2014-2019 UE – WHRI Academy. "G. d'Annunzio" University Coordinator
- 2014-2016 Italian Cystic Fibrosis Foundation - P.I.
- 2012-2013 Italian Cystic Fibrosis Foundation - P.I.
- 2011-2014 Italian Ministry of the University and Scientific Research (PRIN) - Unit Coordinator
- 2011-2013 Italian Cystic Fibrosis Foundation - Co-investigator
- 2010-2012 Italian Cystic Fibrosis Foundation - P.I.
- 2007-2009 Italian Cystic Fibrosis Foundation - P.I.
- 2006-2010 UE VI Framework program – EICOSANOX - Unit Coordinator
- 2005-2007 Italian Ministry of the University and Scientific Research (PRIN program) - Unit Coordinator
- 2005-2007 Italian Cystic Fibrosis Foundation - P.I.
- 2003-2005 Italian Ministry of Health. Finalized Research - Unit Coordinator
- 2002-2004 Italian Ministry of the University and Scientific Research (PRIN program) - Unit Coordinator
- 2001-2004 Italian Ministry of the University and Scientific Research (Firb) - P.I.
- 1998 Italian Foreign Ministry - Spain-Italy integrated actions - P.I.
- 1997 National Research Council - P.I.
- 1991 National Research Council - P.I.

Other Source of Funding

2011-2012 Actelion Pharmaceutical Ltd. "Evaluation of a FPR2/ALX agonist on inflammatory responses in Cystic Fibrosis.

2003-2005 AlfaWassermann S.p.A. "Effect of Licofelone on cancer cell proliferation and survival and on mechanisms of neoangiogenesis"

Patents

European Patent No. EP2597160 - 23.09.2015. Screening tool for anti-inflammatory drug discovery comprising the FPR2/ALX gene promoter.

USA Patent No 9,234,231 B2 - 12.01.2016. Screening tool for anti-inflammatory drug discovery comprising the FPR2/ALX gene promoter.

Italian Patent n. 102016000051449 – 19.11.2018 "Sistema di rilascio della lipossina A_4 mediante membrana polimerica porosa ottenuta con elettrofilatura" (Release system of lipoxin A_4 using porous polymeric membrane obtained by electrospinning).

Italian Patent n. 102017000025741 – 27.06.2019 "Saggi farmacologici per la fibrosi cistica" (Pharmacological assays for cystic fibrosis).

Original Peer-Reviewed Publications

1. **Romano, M.**, Poggi, A., Donati, M.B., Cortellazzo, S., Viero, P., Barbui, T. 1986. Reduced platelet mitogenic activity in myeloproliferative disorders [letter]. *Lancet*. 2: 345.

2. **Romano, M.**, Poggi, A. 1986. Myelofibrosis: A role for Platelet Derived Growth Factor (PDGF)? *Haematologica*. 71: 359-361.

3. **Romano, M.**, Hawiger, J. 1990. Interaction of endotoxic lipid A and lipid X with purified human platelet protein kinase C. *J. Biol. Chem.* 265: 1765-1770.

4. **Romano, M.**, Viero, P., Cortellazzo, S., Barbui, T., Donati, M. B., Poggi, A. 1990. Reduced platelet derived mitogenic activity in patients with Myeloproliferative Diseases. *Haemostasis*. 20: 162-168.

5. **Romano, M.**, Molino, M., Cerletti, C. 1991. Endotoxic Lipid A induces intracellular Ca^{2+} increase in human platelets. *Biochem. J.* 278: 75-80.

6. Fiore, S., **Romano, M.,** Serhan, C.N. 1991. Lipoxin and leukotriene production during receptor-activated interactions between human platelets and cytokine-primed neutrophils. *Adv Prostaglandin Thromboxane Leukot Res*. 21A:93-96.

7. Sheppard, K.-A., Greenberg, S. M., Funk, C. D., **Romano, M.**, Serhan, C. N. 1992. Lipoxin generation by human magakaryocyte-induced 12-lipoxygenase. *Biochim. Biophys. Acta.* 1133:223-234.

8. **Romano, M.**, Serhan, C. N. 1992. Lipoxin generation by permeabilized human platelets. *Biochemistry*. 31:8269-8277.

9. Fiore, S., **Romano, M.**, Reardon, E. M., Serhan, C. N. 1993. Induction of functional Lipoxin A4 receptors in HL-60 cells. *Blood*. 81:3395-3403.

10. Levy, B. D., **Romano, M.**, Reilly, J. J., Drazen, J., Serhan, C. N. 1993. Human alveolar macrophages generate 15-HETE and can produce lipoxins. *J. Clin. Invest.* 92:1572-1579.

11. **Romano, M.**, Chen, X-S., Takahashi, Y., Yamamoto, S., Serhan, C.N. 1993. Lipoxin synthase activity of human platelet 12-Lipoxygenase. *Biochem. J.* 296:127-133.

12. Datta, Y.H., **Romano, M.**, Jacobson, B.C., Serhan, C.N., Ewenstein, B.M. 1995. Peptido-leukotrienes stimulate von Willebrand factor secretion and P-selectin surface expression in human umbilical vein endothelial cells. *Circulation*. 92: 3304-3311.

13. Serhan, C. N., **Romano, M.** 1995. Lipoxin biosynthesis and actions: role of the human platelet LX-Synthase. *J Lipid Mediators Cell Signalling*. 12:293-306.

14. **Romano, M.**, Maddox, J.F., Serhan, C.N. 1996. Activation of human monocytes and the acute monocytic cell line (THP-1) by lipoxins involves unique signaling pathways for lipoxin A4 and lipoxin B4: evidence for differential Ca^{2+} mobilization. *J. Immunol.* 157:2149-2154.

15. Davì, G., **Romano, M.,** Mezzetti, A., Procopio, A., Iacobelli, S., Antidormi, T., Bucciarelli, T., Alessandrini, P., Cuccurullo, F., Bitolo-Bon, G. 1998. Increased levels of soluble P-selectin in hypercholesterolemic patients. *Circulation.* 97:953-957.

16. Kronert, K., Clish, C., **Romano, M.,** Serhan, C.N. 1999. Transcellular regulation of eicosanoids biosyntesis. *Methods Mol. Biol.* 120:119-144.

17. Titos, E., Chiang, N., Serhan, C.N., **Romano, M.,** Gaya J., Pueyo, G., Clària, J. 1999. Hepatocytes are a rich source of novel aspirin-trigged 15-epi-lipoxin A_4 (ATL). *Am. J. Physiol.* 277 (46):C870-C877.

18. **Romano, M.,** Mezzetti, A., Ciabattoni, G., Febo, F., Di Ienno, S., Roccaforte, S., Vigneri, S., Nubile, G., Milani, M., Davì, G. 2000. Fluvastatin reduces soluble P-selectin and ICAM-1 levels in hypercholesterolemic patients: role of nitric oxide. *J. Invest. Med.* 48:183-189.

19. Purello D'Ambrosio, F., Gangemi, F., Merendino, R., Arena, A., Lombardo, G., Valenti, A., **Romano, M.** 2000. Fluticasone propionate reduces serum interleukin 8 in asthmatic patients. *Respiration* 67:348.

20. **Romano, M.,** Collura, M., Iapichino, L., Pardo, F., Di Febbo, C., Falco, A., Lelli Chiesa, P., Vigneri, S., Davì, G. 2001. Endothelial perturbation in cystic fibrosis. *Thromb. Haemost.* 86:1363-1367.

21. **Romano, M.,** Pomilio, M., Vigneri, S., Falco, A., Lelli Chiesa, P., Chiarelli, F., Davì, G. 2001. Endothelial Perturbation in Children and Adolescents with Type I Diabetes: Role of the Immune-inflammatory Reaction. *Diabetes Care.* 24:1674-1678.

22. Catalano, A., **Romano**, **M.,** Robuffo, I., Strizzi, L., Procopio, A. 2001. Methionine Aminopeptidase-2 regulates human mesothelioma cell survival: Role of Bcl-2 expression and telomerase activity. *Am. J. Pathol.* 159:721-731.

23. **Romano, M.,** Catalano, A., Nutini, M., D'Urbano, E., Crescenzi, C., Claria, J., Davì, G., Procopio, A. 2001. 5-Lipoxygenase Regulates Malignant Mesothelial Cell Survival: Involvement of Vascular Endothelial Growth Factor. *FASEB J.* 15:2326-2336.

24. Catalano, A., **Romano, M.,** Martinotti, S., Procopio, A. 2002. Enhanced expression of vascular endothelial growth factor (VEGF) plays a critical role in the tumor progression potential induced by simian virus 40 large T antigen. *Oncogene* 21:2896-2900.

25. Resnati, M., Pallavicini, I., Wang, J.M., Oppenheim, J., Serhan, C.N., **Romano, M.,** Blasi, F. 2002. The fibrinolytic receptor for urokinase activates the G protein-coupled chemotactic receptor FPRL1/LXA4R *Proc. Natl. Acad. Sci. USA* 99:1359-1364.

26. **Romano, M.,** Luciotti, G., Gangemi, S., Marinucci, F., Prontera, C., D' Urbano, E., Davì, G. 2002. Urinary excretion of lipoxin A_4 and related compounds: Development of new extraction techniques for lipoxins. *Lab. Invest.* 82:1253-1254.

27. Fiorucci, S., Menezes de Lima Jr, O., Mencarelli, A., Palazzetti, B., Distrutti, E., McKnight, W., Dicay, M., **Romano, M.,** L., Morelli, A., Wallace, J.L**.** 2002. Cyclooxygenase-2-derived Lipoxin A_4 increases gastric resistance to aspirin-induced damage. *Gastroenterology.* 123:1598-1606.

28. Titos, E., Chiang, N., Serhan, C.N., **Romano, M.,** Gaya, J., Pueyo, G., Claria, J. 2002. Aspirin-triggered 15-epi-lipoxin A4 biosynthesis in rat liver cells. *Adv. Exp. Med. Biol.* 507:199-209.

29. **Romano, M.,** Guagnano, M.T., Pacini, G., Vigneri, S., Falco, A., Sensi, S., Davì, G. 2003. Association of inflammation markers with impaired insulin sensitivity and coagulative activation in obese healthy women. *J. Clin. Endocr. Metab.* 88:5321-5326

30. Guagnano, M.T., **Romano, M.,** Falco, A., Nutini, M., Marinopiccoli, M. Manigrasso, M.R., Pardi, S. Sensi, S., Davì G. 2003. Leptin increase is associated with markers of the hemostatic system in obese healthy women *J. Thromb. Haemost.* 11:2330-2334.

31. Fiorucci, S., Distrutti, E., Menezes de Lima Jr, O., **Romano, M.,** Mencarelli, A., Barbanti, M., Palazzini, E., Morelli, A., Wallace, J.L. 2003. Relative contribution of acetylated cyclo-oxygenase (COX)-2 and 5-lipoxygenase (LOX) in regulating gastric mucosal integrity and adaptation to aspirin. *FASEB J.* 17:1171-1173.

32. Gangemi, S., Basile, G., Merendino, R.A., Minciullo, P., Novick, D., Rubinstein, M., Dinarello, C.A., Lo Balbo, C., Franceschi, C., Basili, S., D'Urbano, E., Davì, G., Nicita-Mauro, V. M., **Romano, M.** 2003. Increased circulating Interleukin-18 levels in centenarians with no signs of vascular disease: Another paradox of longevity? *Exp. Gerontol.* 38:669-672.

33. Gangemi, S., Luciotti, G., D'Urbano, E., Mallamace, A., Santoro, A., Bellinghieri, G., Davì, G., **Romano, M.** 2003. Physical exercise increases urinary excretion of lipoxin A_4 and related compounds. *J. Appl. Physiol.* 94:2237-2240.

34. **Romano, M.**, Claria, J. 2003. Cyclooxygenase-2 and 5-Lipoxygenase converging functions on cell proliferation and tumor angiogenesis: Implications for cancer therapy. *FASEB J.* 17:1986-1995.

35. Fiorucci, S., Santucci, L., Wallace, J.L., Sardina M., **Romano, M.,** Del Soldato, P., Morelli, A. 2003. Interaction of a selective cyclooxygenase-2 inhibitor with aspirin and NO-releasing aspirin in the human gastric mucosa. *Proc. Natl. Acad. Sci. USA.* 100:10937-10941.

36. Federici, M., Pandolfi, A., De Filippis, E.A., Pellegrini, G., Menghini, R., Lauro, D., Cardellini, M., **Romano, M.**, Sesti, G., Lauro, R., Consoli, A. 2004. G972R IRS-1 variant impairs insulin regulation of eNOS in cultured human endothelial cells. *Circulation.*109:399-405.

37. Gangemi, S., Basile, G., Merendino, R.A., Nicita-Mauro, V., **Romano, M.** 2004. Lower platelet count in centenarians correlates with dispersion of the Q-T interval. *Aging Clin. Exp. Res.* 16:169-171.

38. Falco, A., **Romano, M.,** Iapichino, L., Collura, M., Pardo, F., Davì, V., Vigneri, S., Davì, G. 2004. Increased soluble CD40L levels in cystic fibrosis. *J. Thromb. Haemost.* 2:557-560.

39. Catalano, A., Caprari, P., Soddu, S., Procopio, A**., Romano, M.** 2004. 5-Lipoxygenase antagonizes genotoxic stress-induced apoptosis by altering p53 nuclear trafficking. *FASEB J.* 18:1740-1742.

40. **Romano, M.**, Clària, J. 2005. Pharmacological intervention of cyclooxygenase-2 and 5-lipoxygenase pathways: Impact on inflammation and cancer. *Curr. Pharm. Design.* 11:3431-3447.

41. Gangemi, S., Pescara, L., D'Urbano, E., Basile, G., Nicita-Mauro, V., Davì, G., **Romano, M.** 2005. Aging is characterized by a profound reduction in anti- inflammatory lipoxin A_4 levels. *Exp. Gerontol.* 40:612-614.

42. **Romano, M.** 2005. Lipoxin analogs and lipoxin formation in vivo. *Prostag. Leukotr. Ess.* 73:239-243.

43. **Romano, M.** 2006. Lipid mediators: Lipoxin and aspirin-triggered 15-epi- lipoxins. *Inflammation & Allergy - Drug Targets* 5:81-90.

44. **Romano, M.**, Recchia, I., Recchiuti, A. 2007. Lipoxin receptors. *ScientificWorldJournal*. 7:1393-412.

45. Prontera, C., Martelli, N., Evangelista, V., D'Urbano, E., Manarini, S., Recchiuti, A., Dragani, A., Passeri, C., Davì, G., **Romano, M.** 2007. Homocysteine modulates the CD40/CD40L system. *J. Am. Coll. Cardiol.* 49:2182-2190.

46. **Romano, M**. Inflammation resolution: Does the bone marrow have a say? 2008. *Am. J. Hematol.* 83:435-436.

47. Santilli, F., **Romano, M.,** Recchiuti, A., Dragani, A., Falco, A., Lessiani, G., Fioritoni, F., Lattanzio S., Mattoscio, D., De Cristofaro, R., Rocca, B., Davì, G. 2008. Circulating endothelial progenitor cells and residual in vivo thromboxane biosynthesis in low-dose aspirin-treated polycythemia vera patients. *Blood* 112:1085-1090.

48. Pettinella, C., **Romano M.,** Stuppia L., Santilli F., Liani R., Davì G. 2009. Cyclooxygenase-1 haplotype c50t/a-842g does not affect platelet response to aspirin. *Thromb. Haemost.* 101:687-690.

49. Conese, M., **Romano, M**., Furnari, M.L., Copreni, E., De Fino, I., Pardo, F., Luis V. J. Galietta, L.V.J. 2009. New genetic and pharmacological treatments for cystic fibrosis. *Curr. Ped. Rev.* 5:8-27.

50. Renda, G., Zurro, M., **Romano, M.,** De Caterina, R. 2010. Aspirin-triggered lipoxin in patients treated with aspirin and selective vs non-selective COX-2 inhibitors. *Br. J. Clin. Pharmacol.* 69:303-306.

51. **Romano, M.** 2010. Lipoxins and aspirin-triggered lipoxins. *ScientificWorldJournal* 10:1048-1064.

52. Finamore, F., Pieroni, L., Ronci, M., Marzano, V., Levi Mortera, S., **Romano, M.**, Cortese, C., Federici, G., Urbani, A. 2010. Proteomics investigation of human platelets by shotgun

nUPLC-MSE and 2DE experimental strategies: a comparative study. *Blood Transfus.* 8 Suppl 3:s140-s148 DOI 10.2450/2010.021S.

53. Mattoscio, D., Evangelista, V., De Cristofaro, R., Recchiuti, A., Pandolfi, A., Di Silvestre, S., Manarini, S., Martelli, N., Rocca, B., Petrucci, G., Angelini, D.F., Battistini, L., Robuffo, I., Pensabene, T., Pieroni, L., Furnari, M.L., Pardo, F., Quattrucci, S., Lancellotti, S., Davì, G., **Romano, M.** 2010. Cystic fibrosis transmembrane conductance regulator (CFTR) expression in human platelets: Impact on mediators and mechanisms of the inflammatory response. *FASEB J.* 24:3970-3980.

54. Pieroni, L., Finamore, F., Ronci, M., Mattoscio, D., Marzano, V., Mortera, S.L., Quattrucci, S., Federici, G., **Romano, M.,** Urbani, A. 2010. Proteomics investigation of human platelets in healthy donors and cystic fibrosis patients by shotgun nUPLC-MS(E) and 2DE: a comparative study. *Mol. Biosyst.* 7:630-639.

55. Pierdomenico, L., Lanuti, P., Lachmann, R., Grifone, G., Cianci, E., Gialò, L., Pacella, S., **Romano, M.,** Vitacolonna, E., Miscia, S., Marchisio, M. 2011. Diabetes Mellitus During Pregnancy Interferes with the Biological Characteristics of Wharton's Jelly Mesenchymal Stem Cells. *The Open Tissue Engineering and Regenerative Medicine Journal* 4:103-111.

56. Lanuti, P., Santilli, F., Marchisio, M., Pierdomenico, L., Vitacolonna, E., Santavenere, E., Iacone, A., Davì, G., **Romano, M.,** Miscia, S. 2012. A novel flow cytometric approach to distinguish circulating endothelial cells from endothelial microparticles: Relevance for the evaluation of endothelial dysfunction. *J. Immunol. Methods*. 380:16-22.

57. Simiele, F., Recchiuti, A., Mattoscio, D., De Luca, A., Cianci, E., Franchi, S., Gatta, V., Parolari, A., Werba, J.P., Camera, M., Favaloro, B., **Romano, M.** 2012. Transcriptional regulation of the human FPR2/ALX gene: Evidence of a heritable genetic variant that impairs promoter activity. *FASEB J*. 26:1323-33.

58. Vazzana, N., Guagnano, M.T., Cuccurullo, C., Ferrante, E., Lattanzio, S., Liani, R., **Romano, M.**, Davì, G. 2012. Endogenous Secretory RAGE in Obese Women: Association with Platelet Activation and Oxidative Stress. *J. Clin. Endocrinol. Metab*. 97:E1726-1730.

59. Gangemi, S., Patella, V., Cianci, E., Saitta, S., Lattanzio, S., Florio, G., **Romano, M.** 2012. Ultrarush venom immunotherapy triggers the lipoxin A4 inflammation resolution pathway. *Ann. Allerg. Asthma Immunol.* 109:226-227.

60. D'Alimonte, I., Lannutti, A., Pipino, C., Di Tomo, P., Pierdomenico, L., Cianci, E., Antonucci, I., Marchisio, M., **Romano, M.**, Stuppia, L., Caciagli, F., Pandolfi, A., Ciccarelli, R. 2013. Wnt Signaling Behaves as a "Master Regulator" in the Osteogenic and Adipogenic Commitment of Human Amniotic Fluid Mesenchymal Stem Cells. *Stem Cell Rev*. 9:642-654.

61. Recchiuti, A., Codagnone, M., Pierdomenico, A.M., Rossi, C., Mari, VC., Cianci, E., Simiele, F., Gatta, V., **Romano, M.** 2014. Immunoresolving actions of oral resolvin D1 include selective regulation of the transcription machinery in resolution-phase mouse macrophages. *FASEB J*. 28:3090-3102.

62. Pipino, C., Di Tomo, P., Mandatori, D., Cianci, E., Lanuti, P., Cutrona, M.B., Penolazzi, L., Pierdomenico, L., Lambertini, E., Antonucci, I., Sirolli, V., Bonomini, M., **Romano, M.,** Piva, R., Marchisio, M., Pandolfi, A. 2014. Calcium sensing receptor activation by calcimimetic R-568 in human amniotic fluid mesenchymal stem cells: correlation with osteogenic differentiation. *Stem Cells Dev.* 23:2959-2971.

63. Pipino, C., Pierdomenico, L., Di Tomo, P., Di Giuseppe, F., Cianci, E., D'Alimonte, I., Morabito, C., Centurione, L., Antonucci, I., Mariggiò, M.A., Di Pietro, R., Ciccarelli, R., Marchisio, M., **Romano, M.**, Angelucci, S., Pandolfi, A. 2015. Molecular and phenotypic characterization of human amniotic fluid-derived cells. A morphological and proteomic approach. *Stem Cells Dev.* 24:1415-1428.

64. Pierdomenico A.M., Recchiuti, A., Simiele, F., Codagnone, M., Mari, V.C., Davì, G., **Romano, M.** 2015. MicroRNA-181b Regulates ALX/FPR2 Receptor Expression and Proresolution Signaling in Human Macrophages. *J. Biol. Chem.* 290:3592-3600.

65. **Romano, M.,** Cianci, E., Simiele, F., Recchiuti, A. 2015. Lipoxins and aspirin-triggered lipoxins in resolution of inflammation. *Eur. J. Pharmacol.* 760:49-63.

66. Cianci, E., Recchiuti, A., Trubiani, O., Diomede, F., Marchisio, M., Miscia, S., Colas, R.A., Dalli, J., Serhan, C.N., **Romano, M.** 2016. Human Periodontal Stem Cells Release Specialized Pro-resolving Mediators And Carry Immunomodulatory and Pro-healing Properties Regulated by Lipoxins. *Stem Cell Transl. Med.* 5:20-32.

67. Santilli, F., Guagnano, M.T., Innocenti, P., Aceto, L., Vazzana, N., Lattanzio, S., Liani, R., Tripaldi, R., Creato, V., **Romano, M.,** Davì, G. 2016. Pentraxin 3 and Platelet Activation in Obese Patients After Gastric Banding. *Circ J.* 80:502-511.

68. Simiele, F., Recchiuti, A., Patruno, S., Plebani, R., Pierdomenico, A.M., Codagnone, M., **Romano, M.** 2016. Epigenetic regulation of the formyl peptide receptor 2 gene. *BBAGRM* 859:1252-1258.

69. Cianci, E., Trubiani, O., Diomede, F., Merciaro, I., Meschini, I., Bruni, P., Croce, F. **Romano, M.** 2016. Immobilization and delivery of biologically active Lipoxin A4 using electrospinning technology. *Int. J. Pharm.* 515:254-261.

70. Plebani, R., Tripaldi, R., Lanuti, P., Recchiuti, A., Di Silvestre, S., Anile, M., Venuta, F., Prioletta, M., Mucilli, F., Del Porto, P., Marchisio, M., Pandolfi, A., **Romano, M.** 2017. Establishment and long-term culture of human cystic fibrosis endothelial cells. *Lab Invest.* 97:1375-1384.

71. Totani, L., Plebani, R., Piccoli, A., Di Silvestre, S., Lanuti, P., Recchiuti, A., Cianci, E., Dell'Elba, G., Sacchetti, S., Guarnieri, S., Mariggiò, M.A., Mari, V.C., Anile, M., Venuta, F., Del Porto, P., Moretti, P., Prioletta, M., Mucilli, F., Marchisio, M., Pandolfi, A., Evangelista, V., **Romano, M**. 2017. Biological and clinical relevance of CFTR dysfunction in vascular endothelial cells. *Biochim Biophys Acta* 1863:3243-3253.

72. Codagnone, M., Recchiuti, A, Lanuti, P., Pierdomenico, A.M., Cianci, E., Patruno, S., Mari, V.C., Simiele, F., Di Tomo, P., Pandolfi, A., **Romano, M.** 2017. Lipoxin A4 stimulates endothelial miR-126-5p expression and its transfer via microvesicle. *FASEB J.* 31:1856-1866.

73. Pierdomenico, A.M., Patruno, S., Codagnone, M., Simiele, F., Mari, V.C., Plebani, R., Recchiuti, A., **Romano, M.** 2017. microRNA-181b is increased in cystic fibrosis cells and impairs lipoxin A4 receptor-dependent mechanisms of inflammation resolution and antimicrobial defense. *Sci. Rep.* Oct 18;7(1):13519. doi: 10.1038/s41598-017-14055-y.

74. Codagnone, M., Cianci, E., Lamolinara, A., Mari, V.C., Nespoli, A., Arita, M., Bragonzi, A., Iezzi, M., **Romano, M.,** Recchiuti, A. 2018. Resolvin D1 Enhances the Resolution of Lung Inflammation Caused by Long-term Pseudomonas aeruginosa Infection. *Mucosal Immunol*. 11:35-49.

75. Patruno, S., Garrido-Mesa, J., **Romano, M.,** Perretti, M., Montero-Melendez, T. 2018. Ligand Bias and Its Association With Pro-resolving Actions of Melanocortin Drugs. *Front. Pharmacol.* 9:919.

76. **Romano, M.,** Patruno, S., Pomilio, A., Recchiuti, A. 2019. Concise Review: Pro-Resolving Lipid Mediators and Receptors in Stem Cell Biology. *Stem Cells Transl Med*. 8:992-998.

77. Mattoscio, D., Isopi, E., Codagnone, M., Mari, V.C., Lamolinara, A., D'Aurora, M., Cianci, E., Nespoli, A., Franchi, S., Gatta, V., Dubourdeau, M., Moretti, P., Di Sabatino, M., Iezzi, M., **Romano, M.,** Recchiuti, A. 2020. Resolvin D1 reduces lung infection and inflammation activating resolution in cystic fibrosis. *Front. Immunol., in press.*

Most Significant Publications

Levy, B. D., **Romano, M.**, Reilly, J. J., Drazen, J., Serhan, C. N. 1993. Human alveolar macrophages generate 15-HETE and can produce lipoxins. J. Clin. Invest. 92:1572-1579.

Romano, M., Chen, X-S., Takahashi, Y., Yamamoto, S., Serhan, C.N. 1993. Lipoxin synthase activity of human platelet 12-Lipoxygenase. Biochem. J. 296:127-133.

Romano, M., Catalano, A., Nutini, M., D'Urbano, E., Crescenzi, C., Claria, J., Davì, G., Procopio, A. 2001. 5-Lipoxygenase Regulates Malignant Mesothelial Cell Survival: Involvement of Vascular Endothelial Growth Factor. FASEB J. 15:2326-2336.

Resnati, M., Pallavicini, I., Wang, J.M., Oppenheim, J., Serhan, C.N., **Romano, M.,** Blasi, F. 2002. The fibrinolytic receptor for urokinase activates the G protein-coupled chemotactic receptor FPRL1/LXA4R Proc. Natl. Acad. Sci. USA 99:1359-1364.

Prontera, C., Martelli, N., Evangelista, V., D'Urbano, E., Manarini, S., Recchiuti, A., Dragani, A., Passeri, C., Davì, G., **Romano, M.** 2007. Homocysteine modulates the CD40/CD40L system. J. Am. Coll. Cardiol. 49:2182-2190.

Mattoscio, D., Evangelista, V., De Cristofaro, R., Recchiuti, A., Pandolfi, A., Di Silvestre, S., Manarini, S., Martelli, N., Rocca, B., Petrucci, G., Angelini, D.F., Battistini, L., Robuffo, I., Pensabene, T., Pieroni, L., Furnari, M.L., Pardo, F., Quattrucci, S., Lancellotti, S., Davì, G., **Romano, M.** 2010. Cystic fibrosis transmembrane conductance regulator (CFTR) expression in human platelets: Impact on mediators and mechanisms of the inflammatory response. FASEB J. 24:3970-3980.

Simiele, F., Recchiuti, A., Mattoscio, D., De Luca, A., Cianci, E., Franchi, S., Gatta, V., Parolari, A., Werba, J.P., Camera, M., Favaloro, B., **Romano, M.** 2012. Transcriptional regulation of the human FPR2/ALX gene: Evidence of a heritable genetic variant that impairs promoter activity. FASEB J. 26:1323-33.

Pierdomenico A.M., Recchiuti, A., Simiele, F., Codagnone, M., Mari, V.C., Davì, G., **Romano, M.** 2015. MicroRNA-181b Regulates ALX/FPR2 Receptor Expression and Proresolution Signaling in Human Macrophages. J. Biol. Chem. 290:3592-3600.

Cianci, E., Recchiuti, A., Trubiani, O., Diomede, F., Marchisio, M., Miscia, S., Colas, R.A., Dalli, J., Serhan, C.N., **Romano, M.** 2016. Human Periodontal Stem Cells Release Specialized Pro-resolving Mediators And Carry Immunomodulatory and Pro-healing Properties Regulated by Lipoxins. Stem Cell Transl. Med. 5:20-32.

Codagnone, M., Recchiuti, A, Lanuti, P., Pierdomenico, A.M., Cianci, E., Patruno, S., Mari, V.C., Simiele, F., Di Tomo, P., Pandolfi, A., **Romano, M.** 2017. Lipoxin A4 stimulates endothelial miR-126-5p expression and its transfer via microvesicle. FASEB J. 31:1856-1866.

Peer-Reviewed Publications (last ten years)

1. **Romano, M.** 2010. Lipoxins and aspirin-triggered lipoxins. *ScientificWorldJournal* 10:1048-1064.

2. Finamore, F., Pieroni, L., Ronci, M., Marzano, V., Levi Mortera, S., **Romano, M.**, Cortese, C., Federici, G., Urbani, A. 2010. Proteomics investigation of human platelets by shotgun nUPLC-MSE and 2DE experimental strategies: a comparative study. *Blood Transfus.* 8 Suppl 3:s140-s148 DOI 10.2450/2010.021S.

3. Mattoscio, D., Evangelista, V., De Cristofaro, R., Recchiuti, A., Pandolfi, A., Di Silvestre, S., Manarini, S., Martelli, N., Rocca, B., Petrucci, G., Angelini, D.F., Battistini, L., Robuffo, I., Pensabene, T., Pieroni, L., Furnari, M.L., Pardo, F., Quattrucci, S., Lancellotti, S., Davì, G., **Romano, M.** 2010. Cystic fibrosis transmembrane conductance regulator (CFTR) expression in human platelets: Impact on mediators and mechanisms of the inflammatory response. *FASEB J.* 24:3970-3980.

4. Pieroni, L., Finamore, F., Ronci, M., Mattoscio, D., Marzano, V., Mortera, S.L., Quattrucci, S., Federici, G., **Romano, M.,** Urbani, A. 2010. Proteomics investigation of human platelets in healthy donors and cystic fibrosis patients by shotgun nUPLC-MS(E) and 2DE: a comparative study. *Mol. Biosyst.* 7:630-639.

5. Pierdomenico, L., Lanuti, P., Lachmann, R., Grifone, G., Cianci, E., Gialò, L., Pacella, S., **Romano, M.,** Vitacolonna, E., Miscia, S., Marchisio, M. 2011. Diabetes Mellitus During Pregnancy Interferes with the Biological Characteristics of Wharton's Jelly Mesenchymal Stem Cells. *The Open Tissue Engineering and Regenerative Medicine Journal* 4:103-111.

6. Lanuti, P., Santilli, F., Marchisio, M., Pierdomenico, L., Vitacolonna, E., Santavenere, E., Iacone, A., Davì, G., **Romano, M.,** Miscia, S. 2012. A novel flow cytometric approach to distinguish circulating endothelial cells from endothelial microparticles: Relevance for the evaluation of endothelial dysfunction. *J. Immunol. Methods*. 380:16-22.

7. Simiele, F., Recchiuti, A., Mattoscio, D., De Luca, A., Cianci, E., Franchi, S., Gatta, V., Parolari, A., Werba, J.P., Camera, M., Favaloro, B., **Romano, M.** 2012. Transcriptional regulation of the human FPR2/ALX gene: Evidence of a heritable genetic variant that impairs promoter activity. *FASEB J*. 26:1323-33.

8. Vazzana, N., Guagnano, M.T., Cuccurullo, C., Ferrante, E., Lattanzio, S., Liani, R., **Romano, M.**, Davì, G. 2012. Endogenous Secretory RAGE in Obese Women: Association with Platelet Activation and Oxidative Stress. *J. Clin. Endocrinol. Metab*. 97:E1726-1730.

9. Gangemi, S., Patella, V., Cianci, E., Saitta, S., Lattanzio, S., Florio, G., **Romano, M.** 2012. Ultrarush venom immunotherapy triggers the lipoxin A4 inflammation resolution pathway. *Ann. Allerg. Asthma Immunol.* 109:226-227.

10. D'Alimonte, I., Lannutti, A., Pipino, C., Di Tomo, P., Pierdomenico, L., Cianci, E., Antonucci, I., Marchisio, M., **Romano, M.**, Stuppia, L., Caciagli, F., Pandolfi, A., Ciccarelli, R. 2013. Wnt Signaling Behaves as a "Master Regulator" in the Osteogenic and Adipogenic Commitment of Human Amniotic Fluid Mesenchymal Stem Cells. *Stem Cell Rev*. 9:642-654.

11. Recchiuti, A., Codagnone, M., Pierdomenico, A.M., Rossi, C., Mari, VC., Cianci, E., Simiele, F., Gatta, V., **Romano, M.** 2014. Immunoresolving actions of oral resolvin D1 include selective regulation of the transcription machinery in resolution-phase mouse macrophages. *FASEB J*. 28:3090-3102.

12. Pipino, C., Di Tomo, P., Mandatori, D., Cianci, E., Lanuti, P., Cutrona, M.B., Penolazzi, L., Pierdomenico, L., Lambertini, E., Antonucci, I., Sirolli, V., Bonomini, M., **Romano, M.,** Piva, R., Marchisio, M., Pandolfi, A. 2014. Calcium sensing receptor activation by calcimimetic R-568 in human amniotic fluid mesenchymal stem cells: correlation with osteogenic differentiation. *Stem Cells Dev.* 23:2959-2971.

13. Pipino, C., Pierdomenico, L., Di Tomo, P., Di Giuseppe, F., Cianci, E., D'Alimonte, I., Morabito, C., Centurione, L., Antonucci, I., Mariggiò, M.A., Di Pietro, R., Ciccarelli, R., Marchisio, M., **Romano, M.**, Angelucci, S., Pandolfi, A. 2015. Molecular and phenotypic characterization of human amniotic fluid-derived cells. A morphological and proteomic approach. *Stem Cells Dev.* 24:1415-1428.

14. Pierdomenico A.M., Recchiuti, A., Simiele, F., Codagnone, M., Mari, V.C., Davì, G., **Romano, M.** 2015. MicroRNA-181b Regulates ALX/FPR2 Receptor Expression and Proresolution Signaling in Human Macrophages. *J. Biol. Chem.* 290:3592-3600.

15. **Romano, M.,** Cianci, E., Simiele, F., Recchiuti, A. 2015. Lipoxins and aspirin-triggered lipoxins in resolution of inflammation. *Eur. J. Pharmacol.* 760:49-63.

16. Cianci, E., Recchiuti, A., Trubiani, O., Diomede, F., Marchisio, M., Miscia, S., Colas, R.A., Dalli, J., Serhan, C.N., **Romano, M.** 2016. Human Periodontal Stem Cells Release Specialized Pro-resolving Mediators And Carry Immunomodulatory and Pro-healing Properties Regulated by Lipoxins. *Stem Cell Transl. Med.* 5:20-32.

17. Santilli, F., Guagnano, M.T., Innocenti, P., Aceto, L., Vazzana, N., Lattanzio, S., Liani, R., Tripaldi, R., Creato, V., **Romano, M.,** Davì, G. 2016. Pentraxin 3 and Platelet Activation in Obese Patients After Gastric Banding. *Circ J.* 80:502-511.

18. Simiele, F., Recchiuti, A., Patruno, S., Plebani, R., Pierdomenico, A.M., Codagnone, M., **Romano, M.** 2016. Epigenetic regulation of the formyl peptide receptor 2 gene. *BBAGRM* 859:1252-1258.

19. Cianci, E., Trubiani, O., Diomede, F., Merciaro, I., Meschini, I., Bruni, P., Croce, F. **Romano, M.** 2016. Immobilization and delivery of biologically active Lipoxin A4 using electrospinning technology. *Int. J. Pharm.* 515:254-261.

20. Plebani, R., Tripaldi, R., Lanuti, P., Recchiuti, A., Di Silvestre, S., Anile, M., Venuta, F., Prioletta, M., Mucilli, F., Del Porto, P., Marchisio, M., Pandolfi, A., **Romano, M.** 2017. Establishment and long-term culture of human cystic fibrosis endothelial cells. *Lab Invest.* 97:1375-1384.

21. Totani, L., Plebani, R., Piccoli, A., Di Silvestre, S., Lanuti, P., Recchiuti, A., Cianci, E., Dell'Elba, G., Sacchetti, S., Guarnieri, S., Mariggiò, M.A., Mari, V.C., Anile, M., Venuta, F., Del Porto, P., Moretti, P., Prioletta, M., Mucilli, F., Marchisio, M., Pandolfi, A., Evangelista, V., **Romano, M**. 2017. Biological and clinical relevance of CFTR dysfunction in vascular endothelial cells. *Biochim Biophys Acta* 1863:3243-3253.

22. Codagnone, M., Recchiuti, A, Lanuti, P., Pierdomenico, A.M., Cianci, E., Patruno, S., Mari, V.C., Simiele, F., Di Tomo, P., Pandolfi, A., **Romano, M.** 2017. Lipoxin A4 stimulates endothelial miR-126-5p expression and its transfer via microvesicle. *FASEB J.* 31:1856-1866.

23. Pierdomenico, A.M., Patruno, S., Codagnone, M., Simiele, F., Mari, V.C., Plebani, R., Recchiuti, A., **Romano, M.** 2017. microRNA-181b is increased in cystic fibrosis cells and impairs lipoxin A4 receptor-dependent mechanisms of inflammation resolution and antimicrobial defense. *Sci. Rep.* Oct 18;7(1):13519. doi: 10.1038/s41598-017-14055-y.

24. Codagnone, M., Cianci, E., Lamolinara, A., Mari, V.C., Nespoli, A., Arita, M., Bragonzi, A., Iezzi, M., **Romano, M.,** Recchiuti, A. 2018. Resolvin D1 Enhances the Resolution of Lung Inflammation Caused by Long-term Pseudomonas aeruginosa Infection. *Mucosal Immunol*. 11:35-49.

25. Patruno, S., Garrido-Mesa, J., **Romano, M.,** Perretti, M., Montero-Melendez, T. 2018. Ligand Bias and Its Association With Pro-resolving Actions of Melanocortin Drugs. *Front. Pharmacol.* 9:919.

26. **Romano, M.,** Patruno, S., Pomilio, A., Recchiuti, A. 2019. Concise Review: Pro-Resolving Lipid Mediators and Receptors in Stem Cell Biology. *Stem Cells Transl Med*. 8:992-998.

27. Mattoscio, D., Isopi, E., Codagnone, M., Mari, V.C., Lamolinara, A., D'Aurora, M., Cianci, E., Nespoli, A., Franchi, S., Gatta, V., Dubourdeau, M., Moretti, P., Di Sabatino, M., Iezzi, M., **Romano, M.,** Recchiuti, A. 2020. Resolvin D1 reduces lung infection and inflammation activating resolution in cystic fibrosis. *Front. Immunol., in press.*